By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BioFocus and Almac today announced a deal to provide compound screening and profiling services based on Almac's Flexyte fluorescence lifetime assays to BioFocus' customers.

BioFocus has launched an FLT screening and profiling service using the Flexyte assay platform and is offering services against targets such as proteases, phosphatases, and kinases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.